Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 50 50.
DIULO vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Hydralazine is a direct-acting vasodilator that relaxes arteriolar smooth muscle via mechanisms involving interference with calcium ion movement and possibly nitric oxide release. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
1 tablet (hydralazine 50 mg/hydrochlorothiazide 50 mg) orally twice daily, maximum 2 tablets daily.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Hydralazine: 2-8 hours (acetylator phenotype dependent; slow acetylators up to 8h, fast acetylators 1-2h). Hydrochlorothiazide: 6-15 hours (mean 10h).
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Hydralazine: 80% renal (mainly as metabolites, 1-2% unchanged), 10% fecal. Hydrochlorothiazide: >95% renal (unchanged) via organic anion transporters.
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic